COGNITION
https://www.nct-dresden.de/en/trials/900-000002348
https://www.nct-dresden.de/@@site-logo/logo-nct.svg
COGNITION
Section
NCT
Category
Gynecological tumors / Breast cancer
Subcategory
Breast cancer
Trial Type
Register and supportive Studies
Description for experts
COGNITION aims to offer a comprehensive molecular-genetic profiling of the therapy-resistant lesion after neoadjuvant therapy for early high-risk breast cancer patients who present with a residual bulk tumor (non-pCR or high CPS-EG score) after neoadjuvant therapy. This approach allows for an individualised, risk-adapted, biomarker-stratified therapy recommendation following standard post-neoadjuvant therapy in order to decrease the substantial risk of recurrence and metastasis.
Description for laymen
COGNITION aims to offer a comprehensive molecular-genetic profiling of the therapy-resistant lesion after neoadjuvant therapy for early high-risk breast cancer patients who present with a residual bulk tumor (non-pCR or high CPS-EG score) after neoadjuvant therapy. This approach allows for an individualised, risk-adapted, biomarker-stratified therapy recommendation following standard post-neoadjuvant therapy in order to decrease the substantial risk of recurrence and metastasis.
JSON Data
{
"short_title": "COGNITION",
"data_mode": "900",
"data_mode_number": "000002348",
"official_title": "Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with early breast cancer for enrolment on marker driven trials: early high-risk breast carcinoma.",
"accrual_state": "running",
"therapeutic_value": "nonTherapeutic",
"therapieansatz_value": "kurativ",
"therapieintervention_value": "adjuvant",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": null,
"general_contact_email": null,
"general_contact_phone": null,
"hauptpruefer_dd_name": "Prof. Dr. med. Pauline Wimberger",
"description_laie_de": "Die COGNITION-Studie richtet sich an Patientinnen und Patienten mit einer Brustkrebserkrankung in einem fr\u00fchen Stadium (nicht metastasiert), die mit einer neoadjuvanten Therapie behandelt werden. Im Rahmen der COGNITION-Studie findet eine genetische Analyse des Tumors statt, um Ver\u00e4nderungen zu identifizieren, die zielgenau behandelt werden k\u00f6nnen. Optimalerweise findet der Studieneinschluss vor Beginn einer neoadjuvanten Chemotherapie statt, kann jedoch auch noch bei schlechtem Ansprechen auf die Chemotherapie vor der Operation erfolgen",
"description_laie_en": "COGNITION aims to offer a comprehensive molecular-genetic profiling of the therapy-resistant lesion after neoadjuvant therapy for early high-risk breast cancer patients who present with a residual bulk tumor (non-pCR or high CPS-EG score) after neoadjuvant therapy. This approach allows for an individualised, risk-adapted, biomarker-stratified therapy recommendation following standard post-neoadjuvant therapy in order to decrease the substantial risk of recurrence and metastasis.",
"description_expert_de": "Die COGNITION-Studie richtet sich an Patientinnen und Patienten mit einer Brustkrebserkrankung in einem fr\u00fchen Stadium (nicht metastasiert), die mit einer neoadjuvanten Therapie behandelt werden. Im Rahmen der COGNITION-Studie findet eine genetische Analyse des Tumors statt, um Ver\u00e4nderungen zu identifizieren, die zielgenau behandelt werden k\u00f6nnen. Optimalerweise findet der Studieneinschluss vor Beginn einer neoadjuvanten Chemotherapie statt, kann jedoch auch noch bei schlechtem Ansprechen auf die Chemotherapie vor der Operation erfolgen",
"description_expert_en": "COGNITION aims to offer a comprehensive molecular-genetic profiling of the therapy-resistant lesion after neoadjuvant therapy for early high-risk breast cancer patients who present with a residual bulk tumor (non-pCR or high CPS-EG score) after neoadjuvant therapy. This approach allows for an individualised, risk-adapted, biomarker-stratified therapy recommendation following standard post-neoadjuvant therapy in order to decrease the substantial risk of recurrence and metastasis.",
"rechtsgrundlage_value": "BO",
"phase_amg_value": null,
"main_cat_id": 3,
"sub_cat_id": 16
}